KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EBT (2016 - 2025)

Eli Lilly's EBT history spans 17 years, with the latest figure at $8.3 billion for Q4 2025.

  • For Q4 2025, EBT rose 64.07% year-over-year to $8.3 billion; the TTM value through Dec 2025 reached $25.7 billion, up 102.93%, while the annual FY2025 figure was $25.7 billion, 102.93% up from the prior year.
  • EBT reached $8.3 billion in Q4 2025 per LLY's latest filing, up from $7.2 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $8.3 billion in Q4 2025 to a low of $427.2 million in Q3 2023.
  • Average EBT over 5 years is $2.9 billion, with a median of $2.1 billion recorded in 2022.
  • Peak YoY movement for EBT: crashed 72.71% in 2023, then skyrocketed 355.33% in 2025.
  • A 5-year view of EBT shows it stood at $1.8 billion in 2021, then grew by 13.94% to $2.1 billion in 2022, then increased by 19.64% to $2.5 billion in 2023, then skyrocketed by 100.87% to $5.0 billion in 2024, then skyrocketed by 64.07% to $8.3 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's EBT are $8.3 billion (Q4 2025), $7.2 billion (Q3 2025), and $6.8 billion (Q2 2025).